Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label AL101 in Notch-activated adenoid cystic carcinoma
NL-OMON49242Phase 2Active, not recruiting
- Sponsor
- Ayala Pharmaceuticals, Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osugacestat in adenoid cystic carcinoma (ACC) and salivary gland cancer (SGC), sponsored by Ayala Pharmaceuticals, Inc. Primary endpoint: Objective response rate by independent central review. Started May 2020; status: active, not recruiting.
02
Drugs
osugacestat
03
Conditions
adenoid cystic carcinoma (ACC)salivary gland cancer (SGC)
Beyond the preview
Go deeper on NL-OMON49242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49242.